P04.03 Extent of surgery improves the overall survival independently of imaging characteristics in newly diagnosed glioblastoma

Por Capellades, J., Puig, J., Domenech, S., Diaz, R., Oleaga, L., Pujol, T., Camins, A., Majos, C., de Quintana, C., Balana, C.
Publicado no Neuro Oncol (2017)

P05.81 Neurocognitive assessment in cancer patients without central nervous system disease treated with bevacizumab at week 34: an observational transversal multi-centric pilot stu...

Por Panciroli, C, Lucente, G, Cecilia, O, Quiroga, V, Carcereny, E, Pardo, J, Romeo, M, Velarde, J, Villa, S, Balaña, C
Publicado no Neuro Oncol (2018)

Extended-schedule dose-dense temozolomide in refractory gliomas

Por Berrocal, A., Perez Segura, P., Gil, M., Balaña, C., Garcia Lopez, J., Yaya, R., Rodríguez, J., Reynes, G., Gallego, O., Iglesias, L.
Publicado em 2009

SEOM clinical guidelines for anaplastic gliomas (2017)

Por Balañá, C., Alonso, M., Hernandez, A., Perez-Segura, P., Pineda, E., Ramos, A., Sanchez, A. R., Teixidor, P., Verger, E., Benavides, M.
Publicado no Clin Transl Oncol (2017)

Correction to: SEOM clinical guidelines for anaplastic gliomas (2017)

Por Balañá, C., Alonso, M., Hernandez-Lain, A., Perez-Segura, P., Pineda, E., Ramos, A., Sanchez, A. R., Teixidor, P., Verger, E., Benavides, M.
Publicado no Clin Transl Oncol (2018)

P17.04 RANO CRITERIA APPLIED TO A PHASE II RANDOMIZED, MULTICENTER TRIAL COMPARING TEMOZOLOMIDE (TMZ) VS TMZ-PLUS-BEVACIZUMAB (BEV) BEFORE STANDARD TREATMENT IN UNRESECTABLE GLIOBL...

Por Balaña, C., Peñas, R. de las, Sepúlveda, J., Gil, M. Gil, Luque, R., Gallego, O., Reynes, G., Herrero, A., Perez-Segura, P., Berrocal, A.
Publicado em 2014

2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary

Por Losa, F., Iglesias, L., Pané, M., Sanz, J., Nieto, B., Fusté, V., de la Cruz-Merino, L., Concha, Á., Balañá, C., Matías-Guiu, X.
Publicado no Clin Transl Oncol (2018)

Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry

Por Gallego, Oscar, Cuatrecasas, M., Benavides, M., Segura, P. P., Berrocal, A., Erill, N., Colomer, A., Quintana, M. J., Balaña, C., Gil, M., Gallardo, A., Murata, P., Barnadas, A.
Publicado em 2013

Erratum to: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry

Por Gallego, Oscar, Cuatrecasas, M., Benavides, M., Segura, P. P., Berrocal, A., Erill, N., Colomer, A., Quintana, M. J., Balaña, C., Gil, M., Gallardo, A., Murata, P., Barnadas, A.
Publicado no J Neurooncol (2014)

Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study

Por López-Pousa, A, Losa, R, Martín, J, Maurel, J, Fra, J, Sierra, M, Casado, A, García del Muro, J, Poveda, A, Balañá, C, Martínez-Trufero, J, Esteban, E, Buesa, J M
Publicado em 2006

Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A...

Por Poveda, A., López-Pousa, A., Martín, J., Del Muro, J. García, Bernabé, R., Casado, A., Balañá, C., Sanmartín, O., Menéndez, M. D., Escudero, P., Cruz, J., Belyakova, Elena, Menéndez, D., Buesa, J. M.
Publicado em 2005

P14.58 Extending adjuvant temozolomide longer than six cycles doesn’t add any benefit to glioblastoma patients according to the randomized GEINO-014 TRIAL

Por Balana, C, Sepulveda, J, Pineda, E, Vaz, M, Mesia, C, Fuster, J, Girones, R, Muñoz-Langa, J, Navarro, M, Alonso, M, Gil Gil, M, Herrero, A, Estival, A, Gallego, O, Peralta, S, Olier, C, Pérez-Segura, P, Covela, M, Martinez García, M, Domenech, M, Carrato, C, Sanz, C, Velarde, J, Berrocal, A, Luque, R, De las Peñas, R, Del Barco, S
Publicado no Neuro Oncol (2019)